卡尔蛋白蛋白会影响原发性抗脂综合征患者的血小板存活率
Claire K Hoy1, Somanathapura K NaveenKumar1, Sherwin A Navaz1
1University of Michigan, Ann Arbor.
Arthritis & rheumatology (Hoboken, N.J.)
|January 16, 2024
概括
中性粒细胞释放的蛋白质calprotectin在抗脂抗体 (aPL) 相关的血小板缩中升高. 这项研究表明,calprotectin可能是抗脂综合征 (APS) 的生物标志物和治疗标.
科学领域:
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
- 类风湿病学 类风湿病学
背景情况:
- 抗脂综合征 (APS) 的特点是血栓形成和妊娠流产.
- 在APS中,出现了非标准表现,包括血小板缺血.
- 抗脂抗体 (aPL) 介导的血小板缺血的机制和生物标志物尚不清楚.
研究的目的:
- 评估在初级APS和aPL阳性患者中循环calprotectin的存在和临床关联.
- 调查calprotectin在aPL介导的血小板缺血中的机械作用.
主要方法:
- 循环中的calprotectin水平使用化学发光试验进行测量.
- 通过基于染料的测试,评估了对calprotectin的反应中的血小板活力.
- 分析了calprotectin,中性粒细胞计数,C反应蛋白和血小板计数之间的相关性.
主要成果:
- 与健康对照组相比,初级APS和aPL阳性患者的calprotectin水平更高.
- 卡尔蛋白蛋白水平与中性粒细胞计数和C-反应蛋白正相关,与血小板计数负相关.
- 卡尔蛋白质因托尔样受体4和NLRP3-炎症酶激活而诱导aPL介导的血小板缺血,从而降低了血小板活力.
结论:
- 在患有血小板缺血的APS患者中,calprotectin的水平升高.
- 卡尔蛋白可以作为APS血小板缺血的功能生物标志物.
- 卡尔蛋白蛋白代表了与APS相关的血小板缺血的潜在治疗标.
更多相关视频
04:37Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
Published on: May 23, 2025
384
09:13Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
Published on: April 6, 2017
12.0K
相关概念视频
Formation of the Platelet Plug
6.3K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.3K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
525
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525
Anticoagulant Drugs: Low-Molecular-Weight Heparins
701
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
701
Structure and Function of Platelets
1.2K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.2K
